OPTIMIZERX CORP (OPRX) Stock Fundamental Analysis
NASDAQ:OPRX - Nasdaq - US68401U2042 - Common Stock - Currency: USD
OPRX gets a fundamental rating of 5 out of 10. The analysis compared the fundamentals against 37 industry peers in the Health Care Technology industry. The financial health of OPRX is average, but there are quite some concerns on its profitability. OPRX is not overvalued while it is showing excellent growth. This is an interesting combination.
1. Profitability
1.1 Basic Checks
OPRX had positive earnings in the past year.
OPRX had a positive operating cash flow in the past year.
In the past 5 years OPRX reported 4 times negative net income.
In multiple years OPRX reported negative operating cash flow during the last 5 years.
1.2 Ratios
OPRX's Return On Assets of -11.75% is fine compared to the rest of the industry. OPRX outperforms 62.16% of its industry peers.
With a decent Return On Equity value of -17.19%, OPRX is doing good in the industry, outperforming 64.86% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.75% | ||
| ROE | -17.19% | ||
| ROIC | N/A |
ROA(3y)-9.94%
ROA(5y)-6.64%
ROE(3y)-13.38%
ROE(5y)-8.85%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Gross Margin of OPRX (64.45%) is comparable to the rest of the industry.
In the last couple of years the Gross Margin of OPRX has remained more or less at the same level.
OPRX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 64.45% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.49%
GM growth 5Y0.53%
2. Health
2.1 Basic Checks
OPRX does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OPRX has more shares outstanding
OPRX has more shares outstanding than it did 5 years ago.
Compared to 1 year ago, OPRX has an improved debt to assets ratio.
2.2 Solvency
Based on the Altman-Z score of 1.69, we must say that OPRX is in the distress zone and has some risk of bankruptcy.
With a decent Altman-Z score value of 1.69, OPRX is doing good in the industry, outperforming 62.16% of the companies in the same industry.
The Debt to FCF ratio of OPRX is 7.39, which is on the high side as it means it would take OPRX, 7.39 years of fcf income to pay off all of its debts.
Looking at the Debt to FCF ratio, with a value of 7.39, OPRX is in the better half of the industry, outperforming 62.16% of the companies in the same industry.
OPRX has a Debt/Equity ratio of 0.26. This is a healthy value indicating a solid balance between debt and equity.
Looking at the Debt to Equity ratio, with a value of 0.26, OPRX is in line with its industry, outperforming 51.35% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 7.39 | ||
| Altman-Z | 1.69 |
ROIC/WACCN/A
WACC13.02%
2.3 Liquidity
OPRX has a Current Ratio of 2.89. This indicates that OPRX is financially healthy and has no problem in meeting its short term obligations.
Looking at the Current ratio, with a value of 2.89, OPRX is in the better half of the industry, outperforming 78.38% of the companies in the same industry.
OPRX has a Quick Ratio of 2.89. This indicates that OPRX is financially healthy and has no problem in meeting its short term obligations.
With a decent Quick ratio value of 2.89, OPRX is doing good in the industry, outperforming 78.38% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.89 | ||
| Quick Ratio | 2.89 |
3. Growth
3.1 Past
OPRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 32.00%, which is quite impressive.
The Earnings Per Share has been growing by 101.23% on average over the past years. This is a very strong growth
OPRX shows a strong growth in Revenue. In the last year, the Revenue has grown by 28.81%.
OPRX shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 30.22% yearly.
EPS 1Y (TTM)32%
EPS 3Y-9.14%
EPS 5Y101.23%
EPS Q2Q%15.38%
Revenue 1Y (TTM)28.81%
Revenue growth 3Y14.55%
Revenue growth 5Y30.22%
Sales Q2Q%13.92%
3.2 Future
The Earnings Per Share is expected to grow by 34.66% on average over the next years. This is a very strong growth
OPRX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 11.59% yearly.
EPS Next Y22.31%
EPS Next 2Y34.66%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year12.31%
Revenue Next 2Y11.59%
Revenue Next 3YN/A
Revenue Next 5YN/A
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
Although the future Revenue growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 26.24, which means the current valuation is very expensive for OPRX.
Based on the Price/Earnings ratio, OPRX is valued cheaper than 86.49% of the companies in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 28.79, OPRX is valued at the same level.
The Price/Forward Earnings ratio is 21.46, which indicates a rather expensive current valuation of OPRX.
Based on the Price/Forward Earnings ratio, OPRX is valued cheaply inside the industry as 83.78% of the companies are valued more expensively.
Compared to an average S&P500 Price/Forward Earnings ratio of 21.38, OPRX is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.24 | ||
| Fwd PE | 21.46 |
4.2 Price Multiples
Based on the Price/Free Cash Flow ratio, OPRX is valued a bit cheaper than 75.68% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 36.07 | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
OPRX's earnings are expected to grow with 34.66% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.18
PEG (5Y)0.26
EPS Next 2Y34.66%
EPS Next 3YN/A
5. Dividend
5.1 Amount
OPRX does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
8.66
+0.28 (+3.34%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners68.35%
Inst Owner Change-0.45%
Ins Owners10.62%
Ins Owner Change7.08%
Market Cap160.12M
Analysts81.43
Price Target9.91 (14.43%)
Short Float %9.87%
Short Ratio2.73
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)49.54%
Min EPS beat(2)8.43%
Max EPS beat(2)90.65%
EPS beat(4)4
Avg EPS beat(4)61.3%
Min EPS beat(4)8.43%
Max EPS beat(4)130.72%
EPS beat(8)6
Avg EPS beat(8)65.13%
EPS beat(12)9
Avg EPS beat(12)47.52%
EPS beat(16)12
Avg EPS beat(16)52.88%
Revenue beat(2)1
Avg Revenue beat(2)-6.03%
Min Revenue beat(2)-16.43%
Max Revenue beat(2)4.37%
Revenue beat(4)2
Avg Revenue beat(4)-3.57%
Min Revenue beat(4)-16.43%
Max Revenue beat(4)6.46%
Revenue beat(8)5
Avg Revenue beat(8)-1.47%
Revenue beat(12)5
Avg Revenue beat(12)-3.71%
Revenue beat(16)8
Avg Revenue beat(16)-1.77%
PT rev (1m)0%
PT rev (3m)-13.01%
EPS NQ rev (1m)-16.66%
EPS NQ rev (3m)-233.33%
EPS NY rev (1m)15.54%
EPS NY rev (3m)15.41%
Revenue NQ rev (1m)-4.15%
Revenue NQ rev (3m)-11.02%
Revenue NY rev (1m)1.62%
Revenue NY rev (3m)1.23%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 26.24 | ||
| Fwd PE | 21.46 | ||
| P/S | 1.74 | ||
| P/FCF | 36.07 | ||
| P/OCF | 32.75 | ||
| P/B | 1.37 | ||
| P/tB | 261.21 | ||
| EV/EBITDA | N/A |
EPS(TTM)0.33
EY3.81%
EPS(NY)0.4
Fwd EY4.66%
FCF(TTM)0.24
FCFY2.77%
OCF(TTM)0.26
OCFY3.05%
SpS4.98
BVpS6.33
TBVpS0.03
PEG (NY)1.18
PEG (5Y)0.26
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -11.75% | ||
| ROE | -17.19% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 64.45% | ||
| FCFM | 4.82% |
ROA(3y)-9.94%
ROA(5y)-6.64%
ROE(3y)-13.38%
ROE(5y)-8.85%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y3.49%
GM growth 5Y0.53%
F-Score5
Asset Turnover0.54
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.26 | ||
| Debt/FCF | 7.39 | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 10.4% | ||
| Cap/Sales | 0.49% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.89 | ||
| Quick Ratio | 2.89 | ||
| Altman-Z | 1.69 |
F-Score5
WACC13.02%
ROIC/WACCN/A
Cap/Depr(3y)19.52%
Cap/Depr(5y)17.6%
Cap/Sales(3y)0.7%
Cap/Sales(5y)0.62%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)32%
EPS 3Y-9.14%
EPS 5Y101.23%
EPS Q2Q%15.38%
EPS Next Y22.31%
EPS Next 2Y34.66%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)28.81%
Revenue growth 3Y14.55%
Revenue growth 5Y30.22%
Sales Q2Q%13.92%
Revenue Next Year12.31%
Revenue Next 2Y11.59%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y64.5%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year180.73%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y154.73%
FCF growth 3Y154.28%
FCF growth 5YN/A
OCF growth 1Y167.54%
OCF growth 3Y88.49%
OCF growth 5YN/A